Search Results for: CDH5

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CA7 carbonic anhydrase 7
  • Reversible hydration of carbon dioxide
  • Ethoxzolamide
  • Benzthiazide
  • Cyclothiazide
  • Methazolamide
  • Hydroflumethiazide
  • Acetazolamide
  • Zonisamide
  • Diclofenamide
  • Ellagic acid
Novel CDH1 cadherin 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Integrin cell surface interactions
  • Apoptotic cleavage of cell adhesion proteins
  • Adherens junctions interactions
  • RHO GTPases activate IQGAPs
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Gastric cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Breast cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
Novel CDH16 cadherin 16
Novel CDH3 cadherin 3
  • Adherens junctions interactions
  • Hypotrichosis, congenital, with juvenile macular dystrophy
  • Ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM syndrome)
Novel NQO1 NAD(P)H quinone dehydrogenase 1
  • Regulation of ornithine decarboxylase (ODC)
  • Menadione
  • Dicoumarol
  • Duroquinone
  • 3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol
  • ES-936
  • Cibacron Blue
  • Flavin adenine dinucleotide
  • 5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione
  • RH-1
  • Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]
  • 3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE
  • Cannabidiol
Novel PYGB glycogen phosphorylase B
  • Neutrophil degranulation
  • Glycogen breakdown (glycogenolysis)
  • Pyridoxal phosphate
  • Alvocidib
Novel RND3 Rho family GTPase 3
  • Guanosine-5'-Triphosphate
CSK C-terminal Src kinase
  • GAB1 signalosome
  • Phosphorylation of CD3 and TCR zeta chains
  • Integrin signaling
  • PD-1 signaling
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Negative regulation of FLT3
  • Dasatinib
  • Staurosporine
  • TG-100801
  • Fostamatinib
CTNNA1 catenin alpha 1
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate IQGAPs
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Urea
  • Gastric cancer
  • Colorectal cancer
  • Endometrial Cancer
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Thyroid cancer
  • Hepatocellular carcinoma
CTNND1 catenin delta 1
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • InlA-mediated entry of Listeria monocytogenes into host cells
DSP desmoplakin
  • Apoptotic cleavage of cell adhesion proteins
  • Neutrophil degranulation
  • Keratinization
  • Formation of the cornified envelope
  • Zinc
  • Artenimol
  • Zinc acetate
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Naxos disease and Carvajal syndrome
  • Striate palmoplantar keratoderma
  • Skin fragility-woolly hair syndrome
  • Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
EPHA2 EPH receptor A2
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Dasatinib
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Regorafenib
  • Fostamatinib
F2RL2 coagulation factor II thrombin receptor like 2
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Thrombin signalling through proteinase activated receptors (PARs)
FGA fibrinogen alpha chain
  • Platelet degranulation
  • Common Pathway of Fibrin Clot Formation
  • Integrin cell surface interactions
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • MAP2K and MAPK activation
  • Regulation of TLR by endogenous ligand
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Post-translational protein phosphorylation
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Amyloid fiber formation
  • Alteplase
  • Reteplase
  • Anistreplase
  • Tenecteplase
  • Sucralfate
  • Zinc
  • Alfimeprase
  • Ancrod
  • EP-2104R
  • Lanoteplase
  • Thrombin
  • Prothrombin
  • Human thrombin
  • Thrombin alfa
  • Anti-inhibitor coagulant complex
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Afibrinogenemia; Dysfibrinogenemia
  • Inherited thrombophilia
  • Familial amyloidosis
JUP junction plakoglobin
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Neutrophil degranulation
  • Keratinization
  • Formation of the cornified envelope
  • Zinc
  • Zinc acetate
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Naxos disease and Carvajal syndrome
KDR kinase insert domain receptor
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • ABT-869
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
P2RX4 purinergic receptor P2X 4
  • Elevation of cytosolic Ca2+ levels
  • Platelet homeostasis
  • Purinergic signaling in leishmaniasis infection
  • Promethazine
  • Eslicarbazepine acetate
  • Eslicarbazepine
P2RX6 purinergic receptor P2X 6
  • Elevation of cytosolic Ca2+ levels
  • Platelet homeostasis
  • Promethazine

Page 1 out of 2 pages